Search

Your search keyword '"Yang, Dewen"' showing total 2 results
Start Over Author "Yang, Dewen" Topic brain neoplasms
2 results on '"Yang, Dewen"'

1. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.

Author

Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Pope WB, Yang D, Chung C, Knopp MV, Cha S, van den Bent MJ, Chang S, Yung WK, Cloughesy TF, Wen PY, and Gilbert MR

Subjects
Clinical Protocols standards, Clinical Trials as Topic standards, Contrast Media administration & dosage, Humans, Image Enhancement, Brain Neoplasms pathology, Magnetic Resonance Imaging methods, Magnetic Resonance Imaging standards, Neuroimaging methods, Neuroimaging standards
Abstract

A recent joint meeting was held on January 30, 2014, with the US Food and Drug Administration (FDA), National Cancer Institute (NCI), clinical scientists, imaging experts, pharmaceutical and biotech companies, clinical trials cooperative groups, and patient advocate groups to discuss imaging endpoints for clinical trials in glioblastoma. This workshop developed a set of priorities and action items including the creation of a standardized MRI protocol for multicenter studies. The current document outlines consensus recommendations for a standardized Brain Tumor Imaging Protocol (BTIP), along with the scientific and practical justifications for these recommendations, resulting from a series of discussions between various experts involved in aspects of neuro-oncology neuroimaging for clinical trials. The minimum recommended sequences include: (i) parameter-matched precontrast and postcontrast inversion recovery-prepared, isotropic 3D T1-weighted gradient-recalled echo; (ii) axial 2D T2-weighted turbo spin-echo acquired after contrast injection and before postcontrast 3D T1-weighted images to control timing of images after contrast administration; (iii) precontrast, axial 2D T2-weighted fluid-attenuated inversion recovery; and (iv) precontrast, axial 2D, 3-directional diffusion-weighted images. Recommended ranges of sequence parameters are provided for both 1.5 T and 3 T MR systems., (© The Author(s) 2015. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

Published
2015
Full Text
View/download PDF

2. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials

Author

Ellingson, Benjamin M, Bendszus, Martin, Boxerman, Jerrold, Barboriak, Daniel, Erickson, Bradley J, Smits, Marion, Nelson, Sarah J, Gerstner, Elizabeth, Alexander, Brian, Goldmacher, Gregory, Wick, Wolfgang, Vogelbaum, Michael, Weller, Michael, Galanis, Evanthia, Kalpathy-Cramer, Jayashree, Shankar, Lalitha, Jacobs, Paula, Pope, Whitney B, Yang, Dewen, Chung, Caroline, Knopp, Michael V, Cha, Soonme, van den Bent, Martin J, Chang, Susan, Yung, WK Al, Cloughesy, Timothy F, Wen, Patrick Y, Gilbert, Mark R, and Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee

Subjects
Clinical Trials as Topic, clinical trials, Brain Neoplasms, Clinical Trials and Supportive Activities, Oncology and Carcinogenesis, glioblastoma, Neurosciences, Contrast Media, Neuroimaging, Bioengineering, Image Enhancement, Magnetic Resonance Imaging, Brain Disorders, Brain Cancer, Rare Diseases, Clinical Protocols, Clinical Research, Humans, Biomedical Imaging, Brain Tumor Imaging Protocol, Oncology & Carcinogenesis, Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee, MRI, Cancer
Abstract

A recent joint meeting was held on January 30, 2014, with the US Food and Drug Administration (FDA), National Cancer Institute (NCI), clinical scientists, imaging experts, pharmaceutical and biotech companies, clinical trials cooperative groups, and patient advocate groups to discuss imaging endpoints for clinical trials in glioblastoma. This workshop developed a set of priorities and action items including the creation of a standardized MRI protocol for multicenter studies. The current document outlines consensus recommendations for a standardized Brain Tumor Imaging Protocol (BTIP), along with the scientific and practical justifications for these recommendations, resulting from a series of discussions between various experts involved in aspects of neuro-oncology neuroimaging for clinical trials. The minimum recommended sequences include: (i) parameter-matched precontrast and postcontrast inversion recovery-prepared, isotropic 3D T1-weighted gradient-recalled echo; (ii) axial 2D T2-weighted turbo spin-echo acquired after contrast injection and before postcontrast 3D T1-weighted images to control timing of images after contrast administration; (iii) precontrast, axial 2D T2-weighted fluid-attenuated inversion recovery; and (iv) precontrast, axial 2D, 3-directional diffusion-weighted images. Recommended ranges of sequence parameters are provided for both 1.5 T and 3 T MR systems.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results